Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Milo Gatti
Observed names:
Gatti, Milo,
M. Gatti
Institutions:
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
University of Bologna
Observed institutions:
University of Milan,
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda,
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
University of Bologna
ORCID:
0000-0003-3018-3779
Observed ORCID:
0000-0003-3018-3779
OpenAlex ID:
A5040568455
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
2020
·
Emanuel Raschi
, Milo Gatti
, et al.
·
Targeted Oncology
·
168
PDF
Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis
2024
·
Milo Gatti
, Pier Giorgio Cojutti
, et al.
·
Critical Care
·
96
PDF
Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients
2022
·
Milo Gatti
, Pier Giorgio Cojutti
, et al.
·
Critical Care
·
92
PDF
Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections
2021
·
Milo Gatti
, Pier Giorgio Cojutti
, et al.
·
Antibiotics
·
88
PDF
A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol
2021
·
Milo Gatti
, Michele Bartoletti
, et al.
·
Journal of Global Antimicrobial Resistance
·
81
PDF
Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections
2021
·
Marianna Meschiari
, Sara Volpi
, et al.
·
JAC-Antimicrobial Resistance
·
77
PDF
Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use
2024
·
Massimo Sartelli
, Carlo Tascini
, et al.
·
World Journal of Emergency Surgery
·
76
PDF
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system
2020
·
Milo Gatti
, Ippazio Cosimo Antonazzo
, et al.
·
European Journal of Preventive Cardiology
·
75
Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs
2021
·
Milo Gatti
, Massimo Andreoni
, et al.
·
Drug Design Development and Therapy
·
73
PDF
Antimicrobial Dose Reduction in Continuous Renal Replacement Therapy: Myth or Real Need? A Practical Approach for Guiding Dose Optimization of Novel Antibiotics
2021
·
Milo Gatti
, Federico Pea
·
Clinical Pharmacokinetics
·
72
PDF
Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis
2022
·
Milo Gatti
, Matteo Rinaldi
, et al.
·
Clinical Microbiology and Infection
·
67
Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors
2021
·
Milo Gatti
, Federico Pea
·
Expert Review of Clinical Pharmacology
·
65
Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams
2023
·
Milo Gatti
, Federico Pea
·
Expert Review of Anti-infective Therapy
·
63
Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis
2020
·
Milo Gatti
, Emanuel Raschi
, et al.
·
European Journal of Clinical Pharmacology
·
60
PDF
Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring
2022
·
Pier Giorgio Cojutti
, Sara Tedeschi
, et al.
·
Antibiotics
·
58
PDF
Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept
2021
·
Pier Giorgio Cojutti
, Matteo Rinaldi
, et al.
·
International Journal of Antimicrobial Agents
·
56
Advances in the therapy of bacterial bloodstream infections
2019
·
M. Giannella
, M. Bartoletti
, et al.
·
Clinical Microbiology and Infection
·
56
Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID‐19
2020
·
Milo Gatti
, Michele Fusaroli
, et al.
·
British Journal of Clinical Pharmacology
·
54
PDF
Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella review
2020
·
Milo Gatti
, Matteo Bianchin
, et al.
·
European Journal of Internal Medicine
·
54
Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections
2021
·
Milo Gatti
, Federico Pea
·
Current Opinion in Infectious Diseases
·
49
Impact on clinical outcome of follow-up blood cultures and risk factors for persistent bacteraemia in patients with gram-negative bloodstream infections: a systematic review with meta-analysis
2023
·
Milo Gatti
, Cecilia Bonazzetti
, et al.
·
Clinical Microbiology and Infection
·
48
PDF
Bone fracture as a novel immune‐related adverse event with immune checkpoint inhibitors: Case series and large‐scale pharmacovigilance analysis
2021
·
Daria Maria Filippini
, Milo Gatti
, et al.
·
International Journal of Cancer
·
48
PDF
Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis
2023
·
Milo Gatti
, Federica Cosentino
, et al.
·
International Journal of Antimicrobial Agents
·
47
Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues
2021
·
Milo Gatti
, Eleonora Turrini
, et al.
·
Pharmaceuticals
·
46
PDF
The Cytokine Release Syndrome and/or the Proinflammatory Cytokines as Underlying Mechanisms of Downregulation of Drug Metabolism and Drug Transport: A Systematic Review of the Clinical Pharmacokinetics of Victim Drugs of this Drug–Disease Interaction Under Different Clinical Conditions
2022
·
Milo Gatti
, Federico Pea
·
Clinical Pharmacokinetics
·
42
Show more works
View as search
Works count:
197
Citation count:
3,551
H-index:
34
I10-index:
103
Year
Topic
Type